Filing Analysis
LENSAR, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2026. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Fiscal quarter ended June 30, 2026
- The filing includes a press release as Exhibit 99.1
- Information is furnished under Item 2.02 but not 'filed' for liability purposes of Section 18.
LENSAR, Inc. held its annual meeting of stockholders on August 4, 2026, reporting the election of three Class III directors and the approval of several shareholder proposals.
📋 Key Facts
- Annual Meeting held on August 4, 2026; results reported via 8-K filed August 10, 2026.
- Election of Thomas B. Ellis, Richard L. Lindstrom, MD, and William J. Link, PhD as Class III directors.
- Ratification of PricewaterhouseCoopers LLP (PwC) as independent auditor for fiscal year ending Dec 31, 2026.
- Approval of advisory 'Say-on-Pay' compensation proposals (Proposals 3 and 4).
- Shareholders approved a one-year frequency for future advisory votes on executive compensation.
LENSAR, Inc. has appointed Michael A. Rossi as Interim CFO and principal financial officer effective May 29, 2026, via a consulting agreement with Monomoy Advisors LLC. Additionally, the company scheduled its 2026 Annual Meeting for August 4, 2026, with accelerated deadlines for stockholder proposals.
🚩 Red Flags
- Appointment of an 'Interim' CFO rather than a permanent one often signals instability or a transition period.
- The CFO is being hired through a third-party consulting firm (Monomoy Advisors LLC) rather than as a direct employee.
- The 2026 Annual Meeting is being held significantly earlier than the anniversary of the 2025 meeting, necessitating revised deadlines for proposals.
📋 Key Facts
- Michael A. Rossi appointed as Interim CFO effective May 29, 2026.
- Mr. Rossi is provided through Monomoy Advisors LLC at a cash retainer of $375 per hour.
- Mr. Rossi has a background in healthcare turnarounds and previous CFO roles at Harvard Bioscience and ConcertAI.
- The 2026 Annual Meeting of stockholders is scheduled for August 4, 2026.
- The record date for the annual meeting is June 10, 2026.
- Deadline for stockholder proposals and director nominations is June 8, 2026.
LENSAR, Inc. announced its financial results for the first fiscal quarter ended March 31, 2026. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- The press release was issued and furnished on May 8, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- Nicholas T. Curtis, CEO, signed the report.
LENSAR, Inc. announced the resignation of its Chief Financial Officer, Thomas R. Staab, II, effective May 8, 2026. Mr. Staab is leaving to pursue other professional opportunities, and the company has initiated a search for his successor.
🚩 Red Flags
- Loss of a key C-suite executive (CFO) in a micro-cap company can lead to temporary reporting or financial leadership instability.
📋 Key Facts
- CFO Thomas R. Staab, II notified the company of his resignation on April 10, 2026.
- The effective resignation date is set for May 8, 2026.
- Mr. Staab will continue as the principal financial officer through the transition date.
- The company stated the resignation was not the result of any disagreement regarding operations, policies, or practices.
- A search for a new Chief Financial Officer has commenced.
LENSAR, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were disclosed via a press release furnished as an exhibit to the 8-K filing on March 31, 2026.
📋 Key Facts
- Financial results reported for the fiscal quarter and year ended December 31, 2025
- Filing date and report date of March 31, 2026
- Information furnished under Item 2.02 (Results of Operations and Financial Condition)
- Press release included as Exhibit 99.1
- The company is listed on The Nasdaq Stock Market LLC under the symbol LNSR
LENSAR, Inc. and Alcon Research, LLC have mutually terminated their previously announced merger agreement originally dated March 23, 2025. As a result of the termination, LENSAR will retain a $10 million deposit previously paid by Alcon and both parties have released each other from all related liabilities.
🚩 Red Flags
- Termination of a major strategic exit/merger with a significantly larger industry player (Alcon).
- Potential for management distraction and operational disruption resulting from the failed merger process.
- Forward-looking statements highlight risks regarding the company's ability to obtain future financing and the impact of transaction costs.
📋 Key Facts
- The Merger Agreement with Alcon Research, LLC and VMI Option Merger Sub, Inc. was terminated on March 16, 2026.
- LENSAR will retain a $10,000,000 deposit as part of the Termination and Mutual Release Agreement.
- The parties have entered into a mutual release of all claims, damages, and causes of action arising from the merger agreement.
- LENSAR will continue to operate as an independent entity following the termination.
LENSAR, Inc. entered into a Priority Credit Line Agreement with Wells Fargo Bank, N.A. on March 11, 2026, establishing a revolving margin credit facility secured by a designated brokerage account.
📋 Key Facts
- The credit facility is a revolving, non-purpose margin credit line secured by a first-priority lien on a brokerage account (Collateral Account).
- The Company is permitted to borrow up to $9.2 million based on the collateral value in the account.
- Interest rates can be fixed (Treasury Yield plus margin) or variable (SOFR plus margin).
- The filing is an 8-K/A (Amendment No. 1) to clarify terms from the original filing on March 12, 2026.
LENSAR, Inc. entered into a $50 million revolving, non-purpose margin credit facility with Wells Fargo Bank, N.A. The facility is secured by a first-priority lien on a brokerage account, with an initial $10 million in collateral already deposited.
🚩 Red Flags
- The facility is a margin credit line, which carries risk if the value of the financial assets in the Collateral Account drops below required levels.
- Default triggers include the 'insufficiency of the value of the financial assets in the Collateral Account', which could lead to forced liquidation of collateral.
📋 Key Facts
- Agreement dated March 11, 2026, with Wells Fargo Bank, N.A.
- The Priority Credit Line (PCL) Agreement provides up to $50 million in revolving credit.
- Borrowings are secured by a first-priority lien on a designated brokerage account (the Collateral Account).
- Approximately $10 million in collateral has been deposited as of the report date.
- Interest options include fixed rates based on Treasury Yield or variable rates based on SOFR, plus margins.
LENSAR, Inc. issued a status update on February 25, 2026, regarding its pending acquisition by Alcon Research, LLC. The update was disclosed via a press release furnished under Regulation FD.
📋 Key Facts
- LENSAR is in the process of being acquired by Alcon Research, LLC, a major player in the ophthalmic industry.
- The filing was made under Item 7.01 (Regulation FD) on February 25, 2026.
- The acquisition update was formally released through a press release (Exhibit 99.1).
LENSAR, Inc. held its annual meeting of stockholders on December 18, 2025. The company successfully elected three Class II directors and ratified PricewaterhouseCoopers LLP as its independent auditor for the fiscal year ending December 31, 2025.
📋 Key Facts
- Annual Meeting held on December 18, 2025.
- Quorum reached: 17,513,871 votes (approx. 88.07% of total voting power).
- Proposal 1: Nicholas T. Curtis, Todd B. Hammer, and Aimee S. Weisner were elected as Class II directors.
- Proposal 2: Ratification of PricewaterhouseCoopers LLP as independent auditor for FY2025 was approved with 17,469,668 votes in favor.
LENSAR, Inc. filed an 8-K to furnish its quarterly press release for the fiscal quarter ended September 30, 2025.
📋 Key Facts
- The filing relates to financial results announced on November 4, 2025.
- The reporting period is the fiscal quarter ended September 30, 2025.
- The company is an emerging growth company.
- Exhibit 99.1 contains the official press release regarding operations and financial condition.
LENSAR, Inc. has scheduled its 2025 Annual Meeting of Stockholders for December 18, 2025, noting that the meeting will only occur if a pending merger with Alcon Research, LLC is not completed first.
🚩 Red Flags
- The filing notes that the meeting is being held more than 60 days after the previous year's anniversary, necessitating revised (shortened) notice periods for stockholder proposals.
📋 Key Facts
- The 2025 Annual Meeting is scheduled for December 18, 2025, to be held virtually.
- Record date for voting eligibility: Close of business on October 24, 2025.
- The meeting's occurrence is contingent upon the completion of a proposed merger with Alcon Research, LLC; if the merger closes first, the company will become a wholly owned subsidiary and the meeting will be canceled.
- Revised deadlines for stockholder proposals/nominations: October 31, 2025.
LENSAR, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2025. The filing serves as a formal mechanism to furnish the quarterly earnings press release via Exhibit 99.1.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Fiscal quarter ended June 30, 2025
- The filing includes a press release as Exhibit 99.1
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability
LENSAR, Inc. successfully held a special meeting of stockholders on July 2, 2025, where shareholders approved the definitive merger agreement with Alcon Research, LLC. The approval includes the primary Merger Proposal and an advisory vote on executive compensation related to the transaction.
🚩 Red Flags
- None identified in this specific filing; the outcome is a definitive step toward a merger rather than an operational failure.
📋 Key Facts
- Stockholders approved the Agreement and Plan of Merger dated March 23, 2025, between LENSAR and Alcon Research, LLC (Parent).
- The Merger Proposal received 15,983,846 votes in favor.
- A quorum was present, representing 80.69% of all issued and outstanding Common and Series A Convertible Preferred Stock as of the May 15, 2025 record date.
- The advisory 'Merger Compensation Proposal' for executive officers was also approved by stockholders.
- The Adjournment Proposal was deemed unnecessary as a quorum was present and sufficient votes were obtained.
LENSAR, Inc. announced that both it and Alcon Research, LLC have received a 'Second Request' from the FTC regarding their proposed merger. This regulatory action extends the HSR Act waiting period until 30 days after substantial compliance with the request.
🚩 Red Flags
- Regulatory delay: The FTC Second Request introduces uncertainty regarding the timing and ultimate approval of the merger.
- Potential for deal termination if regulatory hurdles are not cleared or if significant concessions are required.
📋 Key Facts
- Merger Agreement originally entered into on March 23, 2025, with Alcon Research, LLC and its subsidiary VMI Option Merger Sub, Inc.
- FTC issued a 'Second Request' for additional information and documentary materials on May 21, 2025.
- The Second Request extends the HSR Act waiting period until 30 days after compliance with the request.
- LENSAR expects to complete the merger in the second half of 2025, pending regulatory approval and closing conditions.
LENSAR, Inc. filed an amendment (8-K/A) to its original May 8, 2025 filing to correct errors in the earnings release for the quarter ended March 31, 2025. The error involved incorrect period references regarding total revenue and net loss figures.
🚩 Red Flags
- Restatement of earnings narrative: While described as a 'period reference' error, any correction to revenue and net loss figures in an earnings release necessitates scrutiny to ensure no underlying financial data was misstated.
- Reporting inaccuracy: Errors in quarterly earnings releases can signal weaknesses in internal controls over financial reporting (ICFR).
📋 Key Facts
- Filing is an Amendment No. 1 (8-K/A) to a previously filed 8-K from May 8, 2025.
- The amendment corrects the narrative description of total revenue and net loss for the quarter ended March 31, 2025.
- The error was specifically related to inadvertent references to incorrect periods in Exhibit 99.1 (Earnings Release).
- A corrected version of the Earnings Release is provided as Exhibit 99.1.
LENSAR, Inc. filed an 8-K to furnish its quarterly earnings press release for the fiscal quarter ended March 31, 2025. This is a routine regulatory filing used to communicate financial results to the market.
📋 Key Facts
- Report date: May 08, 2025
- Reporting period: Fiscal quarter ended March 31, 2025
- The filing includes Exhibit 99.1, which contains the official press release of financial results.
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability.
LENSAR, Inc. has entered into a definitive merger agreement with Alcon Research, LLC to be acquired in an all-cash transaction. The deal includes both immediate cash consideration and contingent value rights (CVRs) based on future performance milestones.
🚩 Red Flags
- Significant termination fee ($8.5M) creates a high barrier for the board to entertain superior offers.
- The CVR component introduces significant uncertainty regarding the total value realized by shareholders.
📋 Key Facts
- Acquisition price: $14.00 per share in cash.
- Contingent Value Rights (CVR): Shareholders receive one CVR per share, representing a potential $2.75 payment if the company achieves 614,000 cumulative Milestone Procedures between Jan 1, 2026, and Dec 31, 2027.
- Total Merger Consideration: Up to $16.75 per share (cash + CVR).
- Termination Fee: The Company must pay Alcon $8,500,000 if the merger is terminated due to a superior proposal or board recommendation change.
- Deposit: Parent will deposit $10,000,000 into a segregated account within five business days of execution.
- Termination Date: The merger must be completed by April 23, 2026 (extendable to July 23, 2026).
LENSAR, Inc. filed an 8-K to announce the release of its financial results for the fiscal quarter and year ended December 31, 2024. The company also scheduled an earnings call to discuss these results and provide a business update.
📋 Key Facts
- Report date: February 27, 2025
- Reporting period: Fiscal quarter and year ended December 31, 2024
- The filing includes an earnings press release as Exhibit 99.1
- An earnings call was scheduled for February 27, 2025, to discuss financial results and business updates.
LENSAR, Inc. issued an 8-K to announce its financial results for the fiscal quarter ended September 30, 2024. The filing serves as a placeholder to furnish the quarterly earnings press release and schedule an earnings call.
📋 Key Facts
- Reporting period: Fiscal quarter ended September 30, 2024.
- Filing date: November 7, 2024.
- The company scheduled an earnings call for November 7, 2024, to discuss results and provide a business update.
- Financial results were released via press release (Exhibit 99.1).
LENSAR, Inc. has mutually terminated a Development Agreement with Oertli Instrumente AG regarding the development of a phacoemulsification component for its ALLY System. The termination is effective immediately as of August 5, 2024, with no termination penalties incurred.
🚩 Red Flags
- Termination of a key development collaboration could signal a shift in product roadmap or difficulty in completing integrated device components.
📋 Key Facts
- Termination of Development Agreement with Oertli Instrumente AG effective August 5, 2024.
- The agreement dated January 29, 2020, focused on the phacoemulsification component of a combined femtosecond laser and phacoemulsification device (the ALLY System).
- No termination penalties were incurred by LENSAR, Inc.
- Intellectual property rights remain with their respective owners as per the original agreement terms.
- The company also issued financial results for the fiscal quarter ended June 30, 2024.
LENSAR, Inc. held its annual meeting of stockholders on May 7, 2024. The results included the election of two Class I directors and the ratification of PricewaterhouseCoopers LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on May 7, 2024.
- Quorum represented approximately 87.94% of total voting power (17,004,638 votes present/represented).
- Elizabeth G. O’Farrell and Gary M. Winer were elected to the Board of Directors as Class I directors.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
LENSAR, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2024. The filing includes a press release and notice of an earnings call scheduled for May 9, 2024.
📋 Key Facts
- Reporting period: Fiscal quarter ended March 31, 2024.
- Filing date: May 9, 2024.
- The company issued a press release (Exhibit 99.1) containing financial results and a business update.
- An earnings call was scheduled for the same day as the filing (May 9, 2024).
LENSAR, Inc. announced the approval of equity compensation grants (RSUs and PSUs) for three key executives on May 3, 2024.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Board approved RSU and PSU grants for Nicholas T. Curtis, Alan B. Connaughton, and Thomas R. Staab, II.
- RSUs vest in four substantially equal annual installments starting May 6, 2024.
- PSU vesting is tied to revenue milestones: 50% if trailing 1-year revenue reaches $75M by Dec 31, 2026; 50% if it reaches $100M by Dec 31, 2027.
- Nicholas T. Curtis (CEO) granted 71,400 RSUs and 71,400 PSUs.
- Alan B. Connaughton granted 45,000 RSUs and 45,000 PSUs.
- Thomas R. Staab, II granted 19,000 RSUs and 19,000 PSUs.
LENSAR, Inc. filed an 8-K to announce its financial results for the fiscal quarter and year ended December 31, 2023. The filing includes a press release (Exhibit 99.1) and announces an earnings call scheduled for March 4, 2024.
📋 Key Facts
- Reporting period: Fiscal quarter and year ended December 31, 2023.
- Filing date: March 4, 2024.
- The company issued a press release containing financial results (Exhibit 99.1).
- An earnings call was held on the same day as the filing to discuss business updates and financial performance.
LENSAR, Inc. announced the adoption of a 2024 Employment Inducement Incentive Award Plan and approved base salary increases for three key officers.
📋 Key Facts
- Board approved the '2024 Employment Inducement Incentive Award Plan' on February 20, 2024.
- The plan allows for awards to new or rehired employees without prior stockholder approval per Nasdaq Rule 5635(c)(4).
- Initially reserved 100,000 shares of common stock for issuance under this new plan.
- Approved a 4% base salary increase for CEO Nicholas T. Curtis, Alan B. Connaughton, and Thomas R. Staab, II, effective January 22, 2024.
LENSAR, Inc. announced the approval of annual cash bonuses for three key executives for the 2023 fiscal year.
📋 Key Facts
- The Board of Directors approved 2023 annual cash bonuses on January 31, 2024.
- Bonuses were awarded to Nicholas T. Curtis, Alan B. Connaughton, and Thomas R. Staab, II.
- Each executive received a bonus at 103% of their respective annual target bonus.